Pulmonary hypertension (PH) is a progressive disorder marked by elevated pulmonary artery (PA) pressure and vascular remodeling, often leading to right heart failure. A key feature is pulmonary artery smooth muscle cells (PASMC) phenotypic switching from a contractile to a synthetic state, which drives medial hypertrophy and vascular occlusion. However, the role of DYRK1A in this process remains unclear.
Objectives
To elucidate DYRK1A's role in PH pathogenesis and identify novel pathways and potential therapeutic targets.
Methods
HySu-induced PH mice underwent PA profiling and smooth muscle cell (SMC)-specific DYRK1A knock-in (DYRK1AKI MYH11). Hemodynamics and remodeling were assessed. Transcriptomics and co-IP/MS mapped DYRK1A downstream effectors. Sodium tanshinone IIA sulfonate (STS) binding was characterized by pull-down, docking, and functional assays, and STS efficacy with DYRK1A targeting was evaluated in HySu-PH mice.
Results
DYRK1A was upregulated in PASMCs from PH models. DYRK1AKI MYH11 exacerbated PA remodeling in HySu-induced PH mice. Mechanistically, DYRK1A enhanced cyclic AMP-dependent protein kinase catalytic subunit alpha (PKACA) activity, which suppressed mitochondrial oxidative phosphorylation and augmented glycolysis, thereby driving PASMC phenotypic transition. Furthermore, STS directly bound and inhibited DYRK1A. This inhibition reduced PKACA activity, restored mitochondrial oxidative phosphorylation, attenuated glycolysis, and suppressed PASMC phenotypic transition. Through DYRK1A, STS alleviated pulmonary arterial remodeling in HySu-induced PH mice.
Conclusions
DYRK1A promotes the phenotypic transition of PASMCs by increasing PKA activity, which shifts cellular metabolism from oxidative phosphorylation to glycolysis, thereby accelerating PA remodeling. Targeting DYRK1A with STS restores mitochondrial function, attenuates PASMC phenotypic transition and alleviates vascular remodeling.
BACKGROUND
Idiopathic pulmonary arterial hypertension (IPAH) is driven by progressive vascular remodeling, particularly smooth muscle cell (SMC) proliferation. Current combination vasodilator therapies have markedly improved outcomes; however, prognosis remains poor in subgroups such as patients with respiratory comorb...
Mariko Kogami, Y. Kato, Satoko Ito et al.· Circulation Research· 0 citations
Findings reveal that Lidd selectively targets the PFKFB3-mediated glycolytic-epigenetic axis to suppress PASMC phenotypic transformation and pulmonary vascular remodeling, positioning it as a promising therapeutic candidate for PH.
Qing-Ye Zeng, Zhen-Zhen Duan, Qian Liu et al.· bioRxiv· 0 citations
Background
Pulmonary arterial hypertension (PAH) is a progressive and potentially fatal disease characterized by increased pulmonary vascular resistance, pulmonary vascular remodeling, and right ventricular failure. To date, therapy has relied mainly on vasodilatory action and has not sufficiently improved patients' lo...
A. Kamińska, Mariana Miller, A. Pakulska et al.· Archiv Euromedica· 0 citations
BACKGROUND
Previous research has highlighted aerobic exercise as beneficial for patients with pulmonary hypertension (PH) and it is often recommended as a key therapeutic approach. However, the specific mechanisms behind these benefits are not yet fully understood.
METHODS
A murine model of hypoxia-induced PH was dev...
Zhu Chen, Zi-Yu He, Xiao-Han Liu et al.· Journal of the American Hear...· 0 citations
BACKGROUND
Pulmonary arterial hypertension (PAH) is a progressive vascular disorder characterized by pulmonary vascular remodeling and endothelial dysfunction. Although several molecular regulators have been implicated in PAH pathogenesis, the key transcriptional networks governing these processes remain incompletely u...